Mesangial homeostasis and pathobiology: Their role in health and disease

Contributions to Nephrology

Volumn 169, Issue , 2011, Pages 6-22

  Herrera, Guillermo A ^a   Turbat Herrera, Elba A ^b   Teng, Jiamin ^a  

^a Nephrocor   (United States)

^b BOSTWICK LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTEGRIN; METALLOPROTEINASE; SIGNAL PEPTIDE;

ARTICLE; GLOMERULUS; HOMEOSTASIS; HUMAN; KIDNEY DISEASE; MESANGIUM; PATHOPHYSIOLOGY; PHYSIOLOGY;

CYTOKINES; GLOMERULAR MESANGIUM; HOMEOSTASIS; HUMANS; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY DISEASES; KIDNEY GLOMERULUS; METALLOPROTEASES;

EID: 84925937147     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000314774     Document Type: Article

References (102)

1. Zimmerman KW: Uber den Bau des Glomerulus der Saugerniere: Weitere Mitteilungen. Z Mikrosk Anat Forsch 1933;32:176-278.
2. Stetler- Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of extracellular matrix. Am J Pathol 1996;148:1345-1350.
3. Morel- Maroger SL, Killen PD, Chi E, Striker GE: The compoition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 1984;51:181-192.
4. Thoenes W, Rumpelt HJ: The obsolescent renal glomerulus - collapse, sclerosis, hyalinosis, fibrosis. A light and electron microscopical study of renal biopsies. Virchows Arch A Pathol Anat Histol 1977;377:1-15.
5. Keeling J, Herrera GA: Human metalloprotinases: characteristics and pathologic role in altering mesangial homeostasis. Microsc Res Tech 2008;71:371-379.
6. Fogo A: Progression and potential regression of glomerulosclerosis. Kidney Int 2001;59:804-819.
7. Fogo AB: Can glomerulosclerosis be reversed? Nat Clin Practie Nephrol 2006;2:290-291.
8. Michael F, Keane WF, Vernier RL, Mauer SM: The glomerular mesangium. Kidney Int 1980;17:141-154.
9. Kriz W, Elger M, Lemley R, Sakai T: The structure of the glomerular mesangium: a biochemical interpretation. Kidney Int 1990; 38(Suppl):52-59.
10. Sakai T, Kriz W: The structural relationship between mesangial cells and basement membrane of the renal glomerulus. Anat Embryol (Berl) 1987;176:373-386.
11. Latta H, Maunsbach AB, Madden SC: The centrolobular region of the renal glomerulus studied by electron microscopy. J Ultrastruct Res 1960;4:455-472.
12. Farquhar MG, Palade GE: Functional evidence for the existence of a third cell type in the renal glomerulus. Phagocytosis of filtration residues by a distinctive third type. J Cell Biol 1962;13:55-87.
13. Schlondorff D: The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J 1987;1:272-281.
14. Schreiner GF: The mesangial phagocyte and its regulation of contractile cell biology. J Am Soc Nephrol 1992;2:S74-S82.
15. Lopez- Armada MJ, Gomez- Guerrero C, Egido J: Receptors for immune complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells. J Immunol 1996;157:2136-2142.
16. El Nahas A- M: Plasticity of kidney cells: role in kidney remodeling and scarring. Kidney Int 2003;64:1553-1563.
17. Herrera GA: Plasticity of mesangial cells: a basis for understanding pathological alterations. Ultrastruct Pathol 2006;30:471-479.
18. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation, and biochemical functions. Eur J Cell Biol 1997;74:111-122.
19. Couchman JR, Beavan LA, McCarthy KJ: Glomerular matrix: synthesis turn over and role in mesangial expansion. Kidney Int 1994;45:328-335.
20. Ronco P, Chatziantoniou C: Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int 2008;74:873-878.
21. Martin J, Eynstone L, Davies M, et al: Induction of metalloproteinases by glomerular mesangial cells stimulated by proteins of the extracellular matrix. J Am Soc Nephrol 2001;12:88-96.
22. Lenz O, Elliot SJ, Stetler- Stevenson WG: Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 2000;11:574-581.
23. Schnaper HW, Kleinman HK: Regulation of cell function by extracellular matrix. Pediatr Nephol 1993;7:96-104.
24. Sugiyama H, Kashihara N, Maesshima Y, Okamoto K, Kanao K, Sekikawa T, Makino H: Regulation of survival and death of mesangial cells by extracellular matrix. Kidney Int 1998;54:1188-1196.
25. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Bohlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579-1586.
26. Haddad E, Moura IC, Arcos- Fajardo M, Macher M- A, Baudoin V, Alberti C, Loirat C, Monteiro RC, Peuchmaur M: Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch- Schonlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003;14:327-337.
27. Gomez- Guerrero C, Gozalez E, Egido J: Evidence for a speific IgA receptor in rat and human mesangial cells. J Immunol 1993;151:7172-7181.
28. Gomez- Guerrero C, Duque N, Egido J: Mesangial cells possess an asialoprotein receptor for affinity for human immunoglobulin A. J Am Soc Nephrol 1998;9:568-576.
29. Roberts AB, McCune BK, Sporn MB: TGF- β: regulation of extracellular matrix. Kidney Int 1992;41:557-559.
30. Thomas S, Vanuystel J, Gruden G, Rodriguez V, Burt D, Gnudi L, Hartley B, Viberti G: Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 2000;11:1236-1243.
31. Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA: Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004;84:440-451.
32. Moura IC, Arcos- Fajardo M, Sadaka C, et al: Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004;15:622-634.
33. Saito K, Shimizu F, Sato T, et al: Modulation of human mesangial cell behaviour by extracellular matrix components - the possible role of interstitial type III collagen. Clin Exp Immunol 1993;91:510-515.
34. Shimizu F, Kawachi H, Orikasa M: Role of mesangial cell change in progressive renal disease. Kidney Blood Press Res 1999;22:5-12.
35. Ayo SH, Radnik RA, Glass WF, Garoni JA, Rampt ER, Appling DR, Kreisberg JI: Increase in extracellular matrix synthesis and mRNA in mesangial cells grown in high glucose medium. Am J Physiol 1991;260:F185-F191.
36. Liu ZH, Striker GE, Settler- Stevenson M, Fukushima P, Patel A, Striker LJ: TNF- α and IL- 1- α induce mannose receptors and apoptosis in glomerular mesangial but not endothelial cells. Am J Physiol 1996;270: C1595-C1601.
37. Tagouri Y, Sanders PW, Zhu I, Picken MM, Winokur TS, Soong S- J, Herrera GA: Glomerulopathic monoclonal light chains potentiate mesangial cell apoptosis in vitro. Lab Invest 1995;92:161A.
38. Khera T, Martin J, Riley S, Steadman R, Phillips AO: Glucose enhances mesangial cell apoptosis. Lab Invest 2006;86:566-577.
39. Silver BJ, Jaffer FE, Abboud HE: Platelet- derived growth factor synthesis in mesangial cells: induction by multiple peptide mitogens. Proc Natl Acad Sci USA 1989;86:1056-1060.
40. Russell WJ, Cardelli J, Harris E, Baier RJ, Herrera GA: Monoclonal light chain- mesangial cells interactions: early signaling events and subsequent pathologic effects. Lab Invest 2001;81:889-703.
41. Razzaque M, Ahsan N, Taguchi T: Role of apoptosis in fibrogenesis. Nephron 2002;90:365-372.
42. Truong LD, Majesky MW, Pindur J: Tenascin is synthesized and secreted by rat mesangial cells in culture and is present in the extracellular matrix in human glomerular disease. J Am Soc Nephrol 1994;4:1771-1777.
43. Turbat- Herrera EA, Isaac J, Sanders PW, Truong LD, Herrera GA: Integrated expression of glomerular extracellular matrix proteins and β1 integrins in monoclonal light chainrelated renal diseases. Mod Pathol 1997;10:485-495.
44. Teng J, Zhang PL, Russell WJ, Zheng LP, Herrera GA: Insights into mechanisms responsible for mesangial alterations associated with fibrogenic glomerulopathic light chains. Nephron Physiol 2003;94:28-38.
45. Truong LD, Pundur J, Barrios R, DAgatti V, Lechago J, Suki W, Majesky M: Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int 1994;45:201-210.
46. Yokosaki Y, Palmer EL, Prieto AL, Crossini KL, Bourdon MA, Pytela R, Sheppard D: The integrin α9β1 mediates cell attachment to a non- RGD site in the third fibronectin repeat of tenascin. J Biol Chem 2994;43:26691-26696.
47. Ooi BS, Cohen DJ, Veis JH: Biology of the mesangial cell in glomerulonephritis - role of cytokines. Proc Soc Exp Biol Med 1996;213:230-237.
48. Sedor JR, Konieczkowski M, Huang S, et al: Cytokines, mesangial cell activation and glomerular injury. Kidney Int 1993;43:S65-S70.
49. Johnson RJ, Iida H, Alpers CE, et al: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. α- smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 1991;87:847-858.
50. Johnson RJ, Floege J, Yoshimura A, et al: The activated mesangial cell: a glomerular myofibroblast? J Am Soc Nephrol 1992;2: S190-S197.
51. Herrera GA, Schultz J, Soong S, Sanders PW: Growth factors in monoclonal light chain- related renal diseases. Hum Pathol 1994;25:883-889.
52. Laiho M, DeCapiro JA, Ludlow JW, Living ston DM, Massague J: Growth inhibition by TGF- β linked to suppression of retino blastoma protein phosphorilation. Cell 1990;62:175-185.
53. Moses HL, Yang EY, Pietenpol JA: TGF- β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990;63:245-247.
54. Border WA, Ruoslahti E: Transforming growth factor- β in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.
55. Roberts AB, Sporn MB: Transforming growth factor- β. Adv Cancer Res 1988;51:107-145.
56. Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth factor- β 1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000;11:80-87.
57. Edwards DR, Murphy G, Reynolds JJ, Whithan SE, Docherty AJ, Angel P, Heath JK: Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899-1904.
58. Zhu L, Herrera GA, Murphy- Ullrich JE, Huang Z- Q, Sanders PW: Pathogenesis of glomerulosclerosis in light chain deposition disease: role for transforming growth factor β. Am J Pathol 1995;147:375-385.
59. Baud L, Fouqueray B, Suberville S, Doublier S: Interleukin 10: a logical candidate for suppressing glomerular inflammation? Exp Nephrol 1998;6:22-27.
60. Baud L, Perez J, Ardaillou R: Dexamethasone and hydrogen peroxide production by mesangial cells during phagocytosis. Am J Physiol 1986;250:F596-F604.
61. Wang JS, Tseng HH, Shih DF, Jou HS, Ger LP: Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 1997;77:404-411.
62. Cattel V: Nitric oxide and glomerulonephritis. Semin Nephrol 1999;19:277-287.
63. Kone BC: Nitric oxide in renal health and disease. Am J Kidney Dis 1997;30:311-333.
64. Kone BC, Baylis C: Biosynthesis and homeostatic role of nitric oxide in the normal kidney. Am J Physiol 1997;272:F561-F578.
65. Davies M, Coles GA, Thomas GJ,Martin J, Lovett DH: Proteinases and the glomerulus: their role in glomerular diseases. Klin Wochenschr 1990;68:1145-1149.
66. Keeling J, Herrera GA: An in- vitro model of light chain deposition disease. Kidney Int 75: 634-645.
67. Keeling J, Herrera GA: Matrix metalloproteinases and mesangial remodeling in light chain- related glomerular damage. Kidney Int 2005;68:1590-1603.
68. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-160.
69. Norman JT, Lewis MP: Matrix metalloproteinases (MMPs) in renal fibrosis. Kidney Int Suppl 1997;54:S61-S63.
70. Heidland A, Sebekova K, Paczek L, Teshner M, Dammrich J, Gaciong Z: Renal fibrosis: Role of impaired proteolysis and potential therapeutic strategies. Kidney Int Suppl 1997;62:S32-S35.
71. El Nahas A- M, Muchaneta- Kubara EC, Essawy M, Soylemezoglu O: Renal fibrosis: insights into pathogenesis and treatment. Int J Biochem Cell Biol 1997;29:55-56
72. Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y: Susceptibility to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 1994;352:216-218.
73. McLennan SV, Yue DK, Turtle JR: Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron 1998;79:293-298.
74. Leehey DJ, Song RH, Alavi N, Singh AK: Decreased degradative enzymes in mesangial cells cultured in high glucose media. Diabetes 1995;44:929-935.
75. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH: Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase- 9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 1996;97:1094-1101.
76. Reuter A, Nestl A, Zwaka RM, Tuckermann J, Waldherr R, Wagner EM, Hoyhtya M, Meyer zum Gottesberger AM, Angel P, Weiher H: Expression of the recessive glomerulosclerosis gene Mpv 17 regulates MMP- 2 expression in fibroblasts, the kidney, and the inner ear of mice. Mol Biol Cell 1998;9:1675-1682.
77. Ahmed AK, El Nahas A- M, Johnson TS: Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int 2007;71:755-763.
78. Steinmann- Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti- Thy 1.1 nephritis. J Am Soc Nephrol 1998;9:397-407.
79. Urushihara M, Kagami S, Kuhara T, Tamaki T, Kuroda Y: Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol Dial Transplant 2002;17:1189-1196.
80. Sanders J- S, van Goor H, Hanemaaijer R, Kallenberg CGM, Stegeman CA: Renal expression of matrix metalloproteinases in human ANCA- associated glomerulonephritis. Nephrol Dial Transplant 2004;19:1412-1419.
81. Salahudeen AK, Kanji V, Reckelhoff JF, Schmidt AM: Pathogenesis of diabetic nephropathy: a radical approach. Nephrol Dial Transplant 1997;12:664-668.
82. McLennan SV, Kelly DJ, Schache M, Waltham M, Dy V, Langham RG, Yue DK, Gilbert RE: Advanced glycation end products decrease mesangial MMP- 7: a role in matrix accumulation of diabetic nephropathy? Kidney Int 2007;72:481-488.
83. Nakamura T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H: Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Diabetes 1993;42:1425-1432.
84. Stix B, Kahne T, Sletten K, Raynes J, Roessner A, Rocken C: Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases- 1,- 2, and - 3. m J Pathol 2001;159:561-570.
85. Lenz O, Elliot SJ, Stetler- Stevenson WG: Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 2000;11:574-581.
86. Chen J, Park H- C, Addabbo F, Ni J,Pelger E, Li H, Plotkin M, Goligorsky MS: Kidney- derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis, and endothelial repair. Kidney Int 2008;74:879-889.
87. Murphy CL, Eulitz M, Hrncic R, Sletten K, Westermark P, Williams T, Macy SD, Wooliver C, Wall J, Weiss DT, Solomon S: Chemical typing of amyloid protein contained in formalin- fixed paraffin- embedded biopsy specimens. Am J Clin Pathol 2001;116:135-142.
88. Picken MM, Herrera GA: The burden of sticky amyloid. Arch Pathol Lab Med 2007;131:850-851.
89. Miyata T, Inagi R, Nangaku M, Imasawa T, Sato M, Izuhara Y, Suzuki D, Yoshino A, Onogi H, Kimura M, Sugiyama S, Kurokawa K: Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. J Clin Invest 2002;109:583-593.
90. Nangaku M, Kurokawa K: Specific tissue distribution of megsin, a novel serpin, in the glomerulus and its up- regulation in IgA nephropathy. Biochem Biophys Res Commun 2001;286:1098-1106.
91. Nangaku M, Miyata T, Suzuki D, Umezono T, Hashimoto T, Wada T, Yagi M, Nagano N, Inagi R, Kurokawa K: Cloning of rodent megsin revealed its up- regulation in mesangioproliferative nephritis. Kidney Int 2001;60:641-652.
92. Suzuki D, Miyata T, Nangaku M, Takano H, Saotome N, Inagi R, Endoh M, Kurokawa K, Sakai H: Expression of megsin mRNA, a novel mesangium- predominant gene, in the renal tissue of various glomerular diseases. J Am Soc Nephrol 1999;10:2606-2613.
93. Inagi R, Miyata T, Imasawa T, Nangaku M, Kurokawa K: Mesangial cell- predominant gene, megsin. Nephrol Dial Transplant 2002;17:32-33.
94. Onogi H, Inagi R, Miyata T, Nangaku M, Kurokawa K: Proteomics and mesangial cell: serpin, megsin, and plasmin; in Thongoboonkerd V, Klein JB (eds): Proteomics in Nephrology. Contrib Nephrol. Basel, Karger, pp 212- 220.
95. Kunter U, Rong S, Djuric Z, Boor P, Muller- Newen G, Yu D, Floege J: Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006;17:2202-2212.
96. Rabelink TJ, van Kooten C: Stem cell therapy for glomerular disease. J Am Soc Nephrol 2006;17:2086-2088.
97. Imai E, Takabatake Y, Mizui M, Isaka Y: Gene therapy in renal diseases. Kidney Int 2004;65:1551-1555.
98. Koh CJ, Atala A: Tissue engineering, stem cells, and cloning: opportunities for regenerative medicine. J Am Soc Nephrol 2004;15:1113-1125.
99. Ito T, Suzuki A, Imai E, et al: Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. J Am Soc Nephrol 2001;12:2625-2635.
100. Imasawa T, Utsunomiya Y, Kawamura T, et al: The potential of bone marrow- derived cells to differentiate to glomerular mesangial cells. J Am Soc Nephrol 2001;12:1401-1409.
101. Poulsom R, Alison MR, Cook T, Jeffery R, Ryan E, Forbes S, Hunt T, Wyles S, Wright NA: Bone marrow stem cells contribute to healing of the kidney. J Am Soc Nephrol Suppl 2003;14:S48-S54.
102. Zerbini G, Piemonti L, Maestroni A, DellAntonio G, Bianchi G: Stem cells and the kidney: a new therapeutic tool? J Am Soc Nephrol Suppl 2006;17:S123-S126.